AU709336C - Anticancer gene therapy by modulation of immune and/or inflammatory response - Google Patents

Anticancer gene therapy by modulation of immune and/or inflammatory response

Info

Publication number
AU709336C
AU709336C AU78159/94A AU7815994A AU709336C AU 709336 C AU709336 C AU 709336C AU 78159/94 A AU78159/94 A AU 78159/94A AU 7815994 A AU7815994 A AU 7815994A AU 709336 C AU709336 C AU 709336C
Authority
AU
Australia
Prior art keywords
agent
contg
immune
inflammatory response
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU78159/94A
Other versions
AU709336B2 (en
AU7815994A (en
Inventor
Bruce Acres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9451366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU709336(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Publication of AU7815994A publication Critical patent/AU7815994A/en
Application granted granted Critical
Publication of AU709336B2 publication Critical patent/AU709336B2/en
Publication of AU709336C publication Critical patent/AU709336C/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Use of a viral vector contg. in its genome a DNA fragment (I) contg. ≥ 1 gene encoding all or part of an agent (A) that modulates the immune and/or inflammatory response for the treatment of cancer in mammals is new. (A) can be a cell surface co-stimulatory molecule, a chemokine, a monoclonal antibody against a lymphocyte surface maker, a super antigen characteristic of an infectious organism (bacterium, virus or parasite), a polypeptide with adjuvant activity or esp. a cytokine. Also claimed is the use of a viral vector with positive tropism for cancer cells contg. in its genome a DNA fragment including ≥ 1 gene, encoding an agent able to destroy cancer cells, under control of appropriate expression elements, for selective delivery of the agent to cancerous tumours.
AU78159/94A 1993-09-29 1994-09-28 Anticancer gene therapy by modulation of immune and/or inflammatory response Expired AU709336C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9311601A FR2710536B1 (en) 1993-09-29 1993-09-29 Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response.
FR93/11601 1993-09-29
PCT/FR1994/001133 WO1995009241A2 (en) 1993-09-29 1994-09-28 Anti-cancer gene therapy by modulation of immune or inflammatory response

Publications (3)

Publication Number Publication Date
AU7815994A AU7815994A (en) 1995-04-18
AU709336B2 AU709336B2 (en) 1999-08-26
AU709336C true AU709336C (en) 2002-06-13

Family

ID=9451366

Family Applications (1)

Application Number Title Priority Date Filing Date
AU78159/94A Expired AU709336C (en) 1993-09-29 1994-09-28 Anticancer gene therapy by modulation of immune and/or inflammatory response

Country Status (12)

Country Link
EP (2) EP0721510B1 (en)
JP (1) JP4094053B2 (en)
AT (2) ATE323774T1 (en)
AU (1) AU709336C (en)
DE (2) DE69434708T2 (en)
DK (2) DK1156119T3 (en)
ES (2) ES2260117T3 (en)
FR (1) FR2710536B1 (en)
HK (1) HK1042728B (en)
PT (2) PT721510E (en)
SG (1) SG96534A1 (en)
WO (1) WO1995009241A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
EP0759695B1 (en) * 1994-05-13 2006-11-08 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants, expressing the gm-csf gene
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB2324960A (en) * 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
EP2261339B1 (en) 1998-05-01 2017-03-22 GlaxoSmithKline Biologicals SA Neisseria meningitidis antigens and compositions
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT1248647E (en) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
EP1366167A2 (en) * 2001-01-26 2003-12-03 Transgene S.A. Biological organism for preparing pharmaceutical compositions for treating mammals
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
JP4413617B2 (en) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Immunization against CHLAMYDIATRACHOMATIS
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
JP4634710B2 (en) * 2002-07-31 2011-02-16 ゲネルクス コーポレーション Microorganisms and cells for tumor diagnosis and treatment
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
RU2376371C2 (en) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Modified recombinant vaccinating viruses and other microorganisms and their application
CN1957082B (en) 2004-03-29 2014-09-17 株式会社嘉尔药物 Novel galectin 9 modification protein and use thereof
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
RU2313349C2 (en) * 2006-01-16 2007-12-27 Михаил Аркадьевич Шурдов Method for treating oncological diseases
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
EP2429580A1 (en) 2009-05-12 2012-03-21 Transgene SA Method for orthopoxvirus production and purification
SG178090A1 (en) 2009-07-21 2012-03-29 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulation and use thereof
RU2704485C2 (en) 2014-12-01 2019-10-29 Трансген Са Stable vaccine virus liquid preparations
CN110769850A (en) 2017-05-15 2020-02-07 扬森疫苗与预防公司 Stable virus-containing compositions
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2583429B1 (en) * 1985-06-18 1989-11-03 Transgene Sa INTERFERON U EXPRESSION VECTOR IN MAMMALIAN CELLS, PROCESS FOR IMPLEMENTING SAME AND PRODUCT OBTAINED, AND PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON U
FR2583770B1 (en) * 1985-06-21 1988-08-19 Transgene Sa EXPRESSION OF HUMAN IL-2 IN MAMMALIAN CELLS BY A RECOMBINANT POXVIRUS
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1993006867A1 (en) * 1991-10-04 1993-04-15 Whitehead Institute For Biomedical Research The regulation of systemic immune responses utilizing cytokines and antigens
DE69230506T2 (en) * 1991-10-25 2000-06-21 Sidney Kimmel Cancer Center Sa LYMPHOKINE GENE THERAPY FOR CANCER IN COMBINATION WITH TUMORANTIGENS
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TARTAGLIA J ET AL. (1990) CRITICAL REVIEWS IN IMMUNOLOGY 10(1):13-30 *

Also Published As

Publication number Publication date
JPH09502993A (en) 1997-03-25
DE69433060D1 (en) 2003-09-25
EP0721510B1 (en) 2003-08-20
WO1995009241A3 (en) 1995-06-22
EP0721510A1 (en) 1996-07-17
HK1042728B (en) 2006-11-24
DE69434708T2 (en) 2007-04-05
EP1156119A3 (en) 2002-10-23
PT721510E (en) 2003-11-28
FR2710536A1 (en) 1995-04-07
DE69433060T2 (en) 2004-06-03
DK1156119T3 (en) 2006-06-06
EP1156119A2 (en) 2001-11-21
WO1995009241A2 (en) 1995-04-06
AU709336B2 (en) 1999-08-26
EP1156119B9 (en) 2006-08-30
PT1156119E (en) 2006-08-31
ATE247714T1 (en) 2003-09-15
EP1156119B1 (en) 2006-04-19
JP4094053B2 (en) 2008-06-04
HK1042728A1 (en) 2002-08-23
DE69434708D1 (en) 2006-05-24
ES2260117T3 (en) 2006-11-01
DK0721510T3 (en) 2003-11-17
SG96534A1 (en) 2003-06-16
AU7815994A (en) 1995-04-18
FR2710536B1 (en) 1995-12-22
ATE323774T1 (en) 2006-05-15
ES2204922T3 (en) 2004-05-01

Similar Documents

Publication Publication Date Title
AU709336C (en) Anticancer gene therapy by modulation of immune and/or inflammatory response
AU2006092A (en) Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US7306793B2 (en) Defective recombinant adenoviruses expressing cytokines for antitumor treatment
EP0668781A4 (en) Lymphokine gene therapy of cancer.
Thompson et al. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
WO2018137643A1 (en) Application of oncolytic virus as immunostimulant for treating tumors and/or cancers
EP0174444A3 (en) Hepatitis surface antigen particle vaccine
CA2363269A1 (en) Dna vaccination for treatment of autoimmune disease
Ju et al. Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity
Wilczyńska et al. Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer.
Wang et al. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer
FR2785293B1 (en) NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC TO NEISSERIA PATHOGENIC STRAINS
EP0662150A4 (en) Maspin, a novel serpin with tumor suppressing activity.
CN1283319C (en) Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene
Sikora First 5 years of gene therapy for cancer.
AU2003206663A1 (en) Microorganism for genetic therapeutic treatment of proliferative diseases
Capone PASSIVE IMMUNOTHERAPY OF HUMAN BREAST TUMORS WITH MONOCLONAL ANTIBODIES.
Connor et al. 298. Treatment of Subcutaneous Melanoma after Vaccination with Cells Expressing Xenoepitopes in the α (1, 3) Galactosiltransferase (αGT) Knockout Mouse Model
WO1998015635A3 (en) Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine
LLOYD CELL TO CELL TRANSFER OF INTERFERON-INDUCED ANTIPROLIFERATIVE ACTIVITY IN VITRO AND ANTIVIRAL ACTIVITY IN VIVO.
MY106737A (en) Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4.
ES8802250A1 (en) A method for obtaining DNA which codes for mutant tumour necrosis factor
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20011022 AND 20011120

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: LEAVE WAS THEREFORE GRANTED TO SERVE FURTHER EVIDENCE.

Opponent name: VIRAX HOLDINGS LIMITED

Effective date: 20020417

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20020124

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20040507 AND 20040726